BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 9650699)

  • 1. C-fos protein expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
    Bergman R; Kerner H; Manov L; Friedman-Birnbaum R
    Am J Dermatopathol; 1998 Jun; 20(3):262-5. PubMed ID: 9650699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mode of c-myc protein expression in Spitz nevi, common melanocytic nevi and malignant melanomas.
    Bergman R; Lurie M; Kerner H; Kilim S; Friedman-Birnbaum R
    J Cutan Pathol; 1997 Apr; 24(4):219-22. PubMed ID: 9138112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas.
    Bergman R; Azzam H; Sprecher E; Manov L; Munichor M; Friedman-Birnbaum R; Ben-Itzhak O
    J Am Acad Dermatol; 2000 Mar; 42(3):496-500. PubMed ID: 10688724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
    Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
    J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S100A6 protein expression is different in Spitz nevi and melanomas.
    Ribé A; McNutt NS
    Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
    Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
    J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors.
    Sprecher E; Bergman R; Meilick A; Kerner H; Manov L; Reiter I; Shafer Y; Maor G; Friedman-Birnbaum R
    J Cutan Pathol; 1999 Feb; 26(2):72-7. PubMed ID: 10082396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study.
    Nagasaka T; Lai R; Medeiros LJ; Brynes RK; McCourty A; Harada T; Saddik M
    Am J Dermatopathol; 1999 Apr; 21(2):115-20. PubMed ID: 10218669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pattern of HMB-45 antibody staining in compound Spitz nevi.
    Bergman R; Dromi R; Trau H; Cohen I; Lichtig C
    Am J Dermatopathol; 1995 Dec; 17(6):542-6. PubMed ID: 8599465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human telomerase RNA component expression in Spitz nevi, common melanocytic nevi, and malignant melanomas.
    Guttman-Yassky E; Bergman R; Manov L; Sprecher E; Shaefer Y; Kerner H
    J Cutan Pathol; 2002 Jul; 29(6):341-6. PubMed ID: 12135464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of p-27 (kip1) in nevi and melanomas.
    Morgan MB; Cowper SE
    Am J Dermatopathol; 1999 Apr; 21(2):121-4. PubMed ID: 10218670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
    Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
    Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
    Piris A; Mihm MC; Hoang MP
    Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of c-kit (CD117) in Spitz nevus and malignant melanoma.
    Isabel Zhu Y; Fitzpatrick JE
    J Cutan Pathol; 2006 Jan; 33(1):33-7. PubMed ID: 16441409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferative activity of primary cutaneous melanocytic tumours.
    Kuwata T; Kitagawa M; Kasuga T
    Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms.
    Googe PB; Flanigan KL; Miedema JR
    Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of melan-A (MART1) in benign melanocytic nevi and primary cutaneous malignant melanoma.
    Busam KJ; Chen YT; Old LJ; Stockert E; Iversen K; Coplan KA; Rosai J; Barnhill RL; Jungbluth AA
    Am J Surg Pathol; 1998 Aug; 22(8):976-82. PubMed ID: 9706977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cadherin expression pattern in melanocytic tumors more likely depends on the melanocyte environment than on tumor cell progression.
    Krengel S; Grotelüschen F; Bartsch S; Tronnier M
    J Cutan Pathol; 2004 Jan; 31(1):1-7. PubMed ID: 14675278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.